{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:05:10Z","timestamp":1789477510732,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Oligometastatic disease (OMD) in neuroendocrine tumors (NET) has hardly been investigated so far and it is unclear how OMD should influence treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The primary objective of this retrospective analysis was to evaluate characteristics and prognosis of the OMD state in patients with NET G1\/G2 of gastroenteropancreatic origin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall study cohort comprised 190 patients. OMD occurred in 29% of patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200955), 58% of those (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200932) had synchronous oligometastases. Oligometastases were limited to one organ in most patients (95%) and primarily involved the liver (83% or\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200943\/52). Median overall survival (OS) from diagnosis was 117.5 months (95% CI 102.4\u2013149.1 months). Calculated from first metastasis, median OS was 102.4 months (95% CI 98.3\u2013117.5 months) and not significantly longer in oligometastatic patients (117.5 months) versus polymetastatic patients (100.2 months). Locoregional treatment of oligometastases was performed in 24\/55 patients (44%) and showed a non-significant trend towards superior survival compared to no such treatment (125.4 versus 99.7 months).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that a low absolute number of metastases alone may not be a clear prognostic factor in NET. It remains unknown if locoregional therapies can achieve long-term disease-free survival in a significant number of oligometastatic NET patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03516-9","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:52:35Z","timestamp":1783349555000},"page":"1023-1031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oligometastatic neuroendocrine tumors: characteristics and prognosis"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-0206","authenticated-orcid":false,"given":"Philipp","family":"Melhorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Postmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5490-2371","authenticated-orcid":false,"given":"Barbara","family":"Kiesewetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"3516_CR1","doi-asserted-by":"crossref","unstructured":"Lamarca A, Bartsch DK, Caplin M, Kos-Kudla B, Kjaer A, Partelli S, et al. European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. J Neuroendocrinol. 2024;36:e13423.","DOI":"10.1111\/jne.13423"},{"key":"3516_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103664","volume":"9","author":"J Hadoux","year":"2024","unstructured":"Hadoux J, Lamarca A, Grande E, Deandreis D, Kaltsas G, Janson ET, et al. Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open. 2024;9:103664.","journal-title":"ESMO Open"},{"key":"3516_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejca.2022.03.007","volume":"168","author":"I Borbath","year":"2022","unstructured":"Borbath I, Garcia-Carbonero R, Bikmukhametov D, Jimenez-Fonseca P, Casta\u00f1o A, Barkmanova J, et al. The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms. Eur J Cancer. 2022;168:80\u201390.","journal-title":"Eur J Cancer"},{"key":"3516_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335\u201342.","journal-title":"JAMA Oncol"},{"key":"3516_CR5","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/ijc.30400","volume":"139","author":"M Riihim\u00e4ki","year":"2016","unstructured":"Riihim\u00e4ki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139:2679\u201386.","journal-title":"Int J Cancer"},{"key":"3516_CR6","doi-asserted-by":"crossref","unstructured":"Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, et al. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO Oncol Pract. 2026;22:19\u201335.","DOI":"10.1200\/OP-25-00133"},{"key":"3516_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8\u201310.","journal-title":"J Clin Oncol"},{"key":"3516_CR8","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21:e18\u2013e28.","journal-title":"Lancet Oncol"},{"key":"3516_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157\u201366.","journal-title":"Radiother Oncol"},{"key":"3516_CR10","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830\u20138.","journal-title":"J Clin Oncol"},{"key":"3516_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844\u201360.","journal-title":"Ann Oncol"},{"key":"3516_CR12","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","volume":"15","author":"A Frilling","year":"2014","unstructured":"Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8\u201321.","journal-title":"Lancet Oncol"},{"key":"3516_CR13","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1245\/s10434-020-08787-x","volume":"27","author":"A Gangi","year":"2020","unstructured":"Gangi A, Howe JR. The landmark series: neuroendocrine tumor liver metastases. Ann Surg Oncol. 2020;27:3270\u201380.","journal-title":"Ann Surg Oncol"},{"key":"3516_CR14","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1111\/ajt.13831","volume":"16","author":"V Mazzaferro","year":"2016","unstructured":"Mazzaferro V, Sposito C, Coppa J, Miceli R, Bhoori S, Bongini M, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant. 2016;16:2892\u2013902.","journal-title":"Am J Transplant"},{"key":"3516_CR15","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2967\/jnumed.115.158899","volume":"56","author":"EI van Vliet","year":"2015","unstructured":"van Vliet EI, van Eijck CH, de Krijger RR, Nieveen van Dijkum EJ, Teunissen JJ, Kam BL, et al. Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3]Octreotate. J Nucl Med. 2015;56:1647\u201353.","journal-title":"J Nucl Med"},{"key":"3516_CR16","first-page":"e240001","volume":"4","author":"JE Nunez","year":"2024","unstructured":"Nunez JE, Ng S, Chen H, Singh S, Hallet J, Law C, et al. Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT. Endocr Oncol. 2024;4:e240001.","journal-title":"Endocr Oncol"},{"key":"3516_CR17","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. (2025). Available from: https:\/\/www.R-project.org\/."},{"key":"3516_CR18","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan LDA, Fran\u00e7ois R, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4:1686.","journal-title":"J Open Source Softw"},{"key":"3516_CR19","unstructured":"Sjoberg D, Baillie M, Fruechtenicht C, Haesendonckx S, Treis T. ggsurvfit: Flexible Time-to-Event Figures. R package version 1.2.0. (2025). Available from: https:\/\/CRAN.R-project.org\/package=ggsurvfit."},{"key":"3516_CR20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.32614\/RJ-2021-053","volume":"13","author":"DD Sjoberg","year":"2021","unstructured":"Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible summary tables with the gtsummary package. R J. 2021;13:570\u201380.","journal-title":"R J"},{"key":"3516_CR21","unstructured":"Clarke E, Sherrill-Mix S, Dawson C. ggbeeswarm: Categorical Scatter (Violin Point) Plots. R package version 0.7.2. (2023). Available from: https:\/\/CRAN.R-project.org\/package=ggbeeswarm."},{"key":"3516_CR22","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/j.ijrobp.2022.07.1091","volume":"114","author":"S Murad","year":"2022","unstructured":"Murad S, Metser U, Brierley J, Ortega C, Kulanthaivelu R, Hinzpeter R, et al. Estimating prevalence of oligometastases at initial staging of neuroendocrine tumors-findings from a 68Ga DOTATATE PET (Ga68PET) population-based registry. Int J Radiat Oncol*Biol*Phys. 2022;114:e186\u2013e7.","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"3516_CR23","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1159\/000513249","volume":"111","author":"BCM Hermans","year":"2021","unstructured":"Hermans BCM, de Vos-Geelen J, Derks JL, Latten L, Liem IH, van der Zwan JM, et al. Unique metastatic patterns in neuroendocrine neoplasms of different primary origin. Neuroendocrinology. 2021;111:1111\u201320.","journal-title":"Neuroendocrinology"},{"key":"3516_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4143\/crt.2022.1460","volume":"55","author":"VS Tan","year":"2023","unstructured":"Tan VS, Palma DA. Top ten lessons learned from trials in oligometastatic cancers. Cancer Res Treat. 2023;55:5\u201314.","journal-title":"Cancer Res Treat"},{"key":"3516_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13244-022-01178-8","volume":"13","author":"SC Olthof","year":"2022","unstructured":"Olthof SC, Wessling D, Winkelmann MT, Rempp H, Nikolaou K, Hoffmann R, et al. Single-centre survival analysis over 10 years after MR-guided radiofrequency ablation of liver metastases from different tumour entities. Insights Imaging. 2022;13:48.","journal-title":"Insights Imaging"},{"key":"3516_CR26","unstructured":"ClinicalTrials.gov. Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) (OligoRARE). (2025). Available from: https:\/\/clinicaltrials.gov\/study\/NCT04498767."},{"key":"3516_CR27","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.hpb.2022.06.009","volume":"24","author":"EM Muttillo","year":"2022","unstructured":"Muttillo EM, Mazzarella G, Picardi B, Rossi S, Cinelli L, Diana M, et al. Treatment strategies for neuroendocrine liver metastases: a systematic review. HPB (Oxf). 2022;24:1832\u201343.","journal-title":"HPB (Oxf)"},{"key":"3516_CR28","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1245\/s10434-017-5839-x","volume":"24","author":"M Fairweather","year":"2017","unstructured":"Fairweather M, Swanson R, Wang J, Brais LK, Dutton T, Kulke MH, et al. Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol. 2017;24:2319\u201325.","journal-title":"Ann Surg Oncol"},{"key":"3516_CR29","doi-asserted-by":"publisher","first-page":"S232","DOI":"10.1016\/j.jvir.2025.01.015","volume":"36","author":"M Soulen","year":"2025","unstructured":"Soulen M, Wileyto E, Dey C, El-Haddad G, Garcia-Monaco R, Fidelman N, et al. Abstract No. LBA7 Randomized Embolization Trial for NeuroEndocrine tumors (RETNET). J Vasc Interv Radiol. 2025;36:S232.","journal-title":"J Vasc Interv Radiol"},{"key":"3516_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/SLA.0b013e3181bdf8cf","volume":"251","author":"D Elias","year":"2010","unstructured":"Elias D, Lefevre JH, Duvillard P, Go\u00e9r\u00e9 D, Dromain C, Dumont F, et al. Hepatic metastases from neuroendocrine tumors with a \u201cthin slice\u201d pathological examination: they are many more than you think. Ann Surg. 2010;251:307\u201310.","journal-title":"Ann Surg"},{"key":"3516_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1200\/JCO.2012.44.2905","volume":"31","author":"MS Khan","year":"2013","unstructured":"Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 2013;31:365\u201372.","journal-title":"J Clin Oncol"},{"key":"3516_CR32","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.annonc.2021.08.1746","volume":"32","author":"IM Modlin","year":"2021","unstructured":"Modlin IM, Kidd M, Falconi M, Filosso PL, Frilling A, Malczewska A, et al. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility. Ann Oncol. 2021;32:1425\u201333.","journal-title":"Ann Oncol"},{"key":"3516_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000471879","volume":"105","author":"A Sundin","year":"2017","unstructured":"Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology. 2017;105:212\u201344.","journal-title":"Neuroendocrinology."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03516-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:13:52Z","timestamp":1789474432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03516-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10,5]]}},"alternative-id":["3516"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03516-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest related to the present work. BK received honoraria for lectures or advisory board participation from the following for-profit companies (all outside of the submitted work): from AAA, AstraZeneca, BMS, Boehringer Ingelheim, Ipsen, MSD, Novartis, Eli Lilly, Roche, and Janssen Cilag. MR received honoraria for lectures or advisory board participation from the following for-profit companies (all outside of the submitted work): AbbVie, Gilead, Galapagos Pharma, Celgene, BMS, Ipsen, Novartis, Roche, Eisai, and Eli Lilly. All other authors have no disclosures to report.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study has received approval from the local Ethics Committee of the Medical University of Vienna (EK No: 1966\/2023). Informed consent was not required due to the retrospective design. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"ETHICS AND CONSENT TO PARTICIPATE","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Artificial intelligence (AI)-based technologies were used in the conduct of this study. ChatGPT version 4 and newer (OpenAI, Inc.; 2023\u20132026;\n                      \n                      ) was used to support R programming for statistical analyses and data visualization. The author(s) reviewed all outputs of this tool\/service and edited the content as needed and take(s) full responsibility for the accuracy and integrity of this work.","order":3,"name":"Ethics","label":"use of artificial intelligence","group":{"name":"EthicsHeading","label":"Ethics"}}]}}